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microRNA -19b is a sex-dependent regulator of posttraumatic stress symptoms and widespread pain 
 
Abstract 
  
Posttraumatic widespread pain (PTWP) and posttraumatic stress symptoms (PTSS) are frequent forms 
of trauma that occur at different rates in women and men. Genetic approaches to study pathways using model 
organisms and mutants have identified hundreds of genes correlated with PTWP/PTSS. Our lab sought to 
identify microRNAs (miRNAs) that contribute to sex-dependent differences in vulnerability to these outcomes. In 
the current study, we first identified miRNA that are predicted to regulate PTWP/PTSS genes using Monte Carlo 
simulations. We found that the most significant miRNA predicted to target PTWP/PTSS genes was miR-19b, a 
microRNA that has been shown previously to be regulated in response to estrogen and stress exposure. Next, 
we assessed whether miR-19b expression predicts PTWP/PTSS in a cohort of individuals experiencing motor 
vehicle collision, one of the most common forms of trauma currently experienced by Americans. Logistic 
regression demonstrated a sex dependent relationship between initial miR-19b levels following motor vehicle 
collision and later development of PTWP/ PTSS. The sex-dependent expression of miR-19b was also observed 
in a rat model of single prolonged stress, which is thought to be analogous to PTSS. We found miR-19b to be 
regulated by 17-β-estradiol in rat dorsal root ganglion neurons and amygdala, which are neural tissues commonly 
implicated in PTSS. The potential importance of miR-19b to PTWP/PTSS pathogenesis is highlighted by results 
showing that miR-19b can directly bind a number of pain and PTSS associated transcripts including circadian 
rhythm pathway genes. Together, our results suggest that miR-19b plays a regulatory role in PTWP and PTSS 
development following trauma/stress exposure. Thus, the level of miR-19b expression following motor vehicle 
collision may predict PTWP/PTSS and enable preventative treatment. 
 
 
 
 
 
Introduction 
 
Motor vehicle collision (MVC) is one of the most common traumatic stress exposures worldwide.1 For 
every 10 individuals experiencing MVC, evidence suggests that two will develop persistent posttraumatic 
widespread pain (PTWP) and three will develop posttraumatic stress symptoms (PTSS).2,3 These morbid 
sequelae of traumatic stress exposures such as MVC frequently co-occur,4-9 suggesting shared pathogenic 
mechanisms, and are more common in women,10-13 suggesting that such mechanisms may differ in women and 
men. However, biologic mechanisms responsible for PTWP and PTSS and contributing to sex differences in 
these adverse outcomes remain poorly understood, despite increasing evidence indicating that PTSS and pain 
processing are sex-dependent14-20. 
microRNA (miRNA) are small non-coding RNA molecules that regulate gene expression by binding to 
target mRNA. Because a single miRNA can regulate many different gene transcripts, each miRNA can act as a 
gene regulatory hub. Previous studies have shown that the study of miRNA can be a valuable tool for gaining 
insight into PTSS and PTWP pathogenesis (e.g.21-30). However, many of these previous studies used 
predominately male cohorts24,25,31,32 or focused on a single sex in animal model studies23,33-36. Therefore, whether 
miRNA expression levels predict PTSS and PTWP in a sex-dependent manner has not been addressed, despite 
evidence indicating that miRNA expression might be differentially regulated in men and women21,37-40. 
The current study used an unbiased in silico approach to first identify PTSS and pain miRNA regulatory 
hubs; that is, miRNA that are predicted to regulate more PTSS and pain- associated transcripts than expected 
by chance41. The top candidate miRNA regulatory hub, miR-19, was then assessed for differential expression in 
males and females who developed PTSS and/or PTWP vs those who recovered following MVC. Secondary 
analyses identified whether sex-dependent expression extended to nervous system tissues relevant to PTSS 
and PTWP and identified relevant pathways/transcripts regulated by miR-19. 
  
 
 
Materials/Subjects and Methods  
 
Bioinformatics  
Few studies evaluating genes associated specifically with post-traumatic widespread pain (PTWP) have 
been performed; genes associated with pain outcomes more generally were identified via the following pain gene 
databases: PainNetworks,42 Algynomics Pain Research Panel v2.0,43 and the PainGenes Database44 (n = 560 
unique genes, Supplementary Table 1). A structured literature review of peer-reviewed original research and 
review articles written in English was performed in May 2015 to identify genes previously associated with PTSS 
related phenotypes (n = 154 genes, Supplementary Table 2) using the following search terms: post-traumatic 
stress disorder, anxiety, attention deficit hyperactivity disorder, bipolar disorder, memory, panic disorder, 
depression, neuroticism, seasonal affective disorder, substance abuse, schizophrenia, obsessive compulsive 
disorder, OR social behavior AND gene, genetic, GWAS, OR transcript. miRNAs predicted to bind to the 3’UTR 
of these identified pain or PTSS genes (n = 629) were then identified using TargetScan 7.0.45  
Monte Carlo simulations (x10,000) consisting of randomly selected sets of genes, normalized to 3’UTR 
length, were used to generate a distribution of the number of predicted pain and PTSS gene targets for each 
known human mature miRNA (miR-Base v.21).41 This distribution was used to identify miRNA with the greatest 
preferential binding to genes previously associated with pain, PTSS, and pain and PTSS phenotypes. 
The ontology relationship between PTWP/PTSS genes predicted to be targeted by miR-19b was assessed 
using the DAVID v6.7 online algorithm (https://david.ncifcrf.gov/home.jsp).46 All miR-19b predicted target genes 
were input into DAVID and the ‘Gene Ontology Biological Process 1’ annotation was selected.  
Predicted miRNA/mRNA binding duplex/hybrids were determined using the RNA Hybrid online algorithm 
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/).47 
 
MVC Cohort Study 
This prospective longitudinal study enrolled African American individuals ≥ 18 and ≤ 65 years of age who 
presented within 24 hours of MVC to one of eleven emergency departments (EDs) in six states/districts 
(Michigan, Pennsylvania, Florida, Alabama, Massachusetts, and Washington D.C.) between July 2012 and July 
 
 
2015. The study only enrolled African Americans because of the pressing need for pain studies that focus on 
understudied, high risk groups.48-50 This study has been described in detail previously.51 In brief, individuals who 
did not have a fracture or other injury requiring hospital admission were screened for eligibility. Patients who 
were not alert and oriented were excluded, as were patients who did not self-identify as African American, were 
pregnant, prisoners, unable to read and understand English, or taking opioids above a total daily dose of 30 mg 
of oral morphine or equivalent. The study was approved by the institutional review boards of all participating 
hospitals. Each participant provided written informed consent before enrollment. 
 
Pain and PTSS assessments and outcome definitions in humans 
MVC-related pain intensity and distribution in the past week was assessed six months following MVC using 
the modified Regional Pain Scale.52 Pain intensity was evaluated in each of 19 body regions53 via a 0 (no pain) 
to 10 (maximum possible pain) numeric rating scale (NRS).54 PTWP was defined according to American College 
of Rheumatology 1990 criteria (i.e., axial pain, left and right sided pain, and upper and lower segment pain).55 
MVC-related PTSS were assessed six months following MVC using the Impact of Event Scale: Revised 
(IESR).56 This 22-item questionnaire includes avoidance, intrusion and hyperarousal subscales. Scores range 
from 0-88; a validated cut-off of 33 was used to define individuals with substantial PTSS.57 
Distress in the ED was measured using the Peritraumatic Distress Inventory, a 13-item questionnaire 
assessing the level of distress experienced immediately after a traumatic event.58 Each item on the questionnaire 
was evaluated using a 0 (no distress) to 4 (high distress) numeric rating scale. A validated cut-off of 23 was used 
to identify those with substantial distress59; this was also the mean and median level of distress in the cohort. 
 
Statistical analyses 
MVC cohort sociodemographic characteristics were summarized using standard descriptive statistics. 
Logistic regression analyses adjusted for participant age and ED study site were used to assess the relationship 
between miR-19b expression levels and PTSS or PTWP outcomes 6 months following MVC, and to derive odds 
ratios (ORs) and p-value significance. miR-19b is expressed across almost all cell types115 and at high levels in 
whole blood; therefore miR-19b sequencing reads were divided by 1000 and ORs can be interpreted as 
 
 
increased odds per 1000 sequencing reads of miR-19b. Sex- and stress-dependent effects were evaluated using 
interaction variables (miR-19b*stress and miR-19b*sex) because of evidence that such interactions are 
frequently present and important (e.g.60-65). Differences in ED miR-19b expression levels between women and 
men who did and did not subsequently develop PTSS or PTWP at 6 months were evaluated by comparing mean 
expression levels in the two groups. Bivariate correlations were used to determine Pearson correlation 
coefficients and p-values for the relationship between miR-19b and potential miR-19b regulated transcripts. 
Statistical analyses were carried out using SPSS software v24.0 or SAS software v9.4.  
 
Animals  
Experiments were performed on adult female and male Sprague Dawley rats (180–300 g; Charles River, 
Hollister, CA, Raleigh, NC, and Kingston, NY). Rats were housed under a 12-hour light/dark cycle in the 
Laboratory Animal Resource Center of the University of California, San Francisco, in the Division of Laboratory 
Animal Medicine at The University of North Carolina at Chapel Hill, or in the Veterinary Medical Unit at The 
University of Michigan. Animal care and use conformed to NIH guidelines. Experimental protocols were approved 
by the Institutional Animal Care and Use Committee at each university.  
 
Animal stress exposures 
Unpredictable Sound Stress: The details of the unpredictable sound stress (USS) protocol have been 
reported previously.66-69 Exposure to sound stress occurred over 4 days, on days 1, 3, and 4. Animals were 
placed in a soundproof chamber in sets of three individual cages that were positioned 25 cm from a speaker that 
emitted a 105-dB tone of mixed frequencies (11 to 19 kHz). Over a period of 30 min, rats were exposed to 5- or 
10-s sound epochs each minute at random intervals during the minute. Following each stress session, animals 
were returned to the animal facility. Two weeks following the final stressor, animals were tested for pain 
hypersensitivity using von Frey monofilaments on the left hind paw following injection of the algogen 
prostaglandin E2. Control animals were left undisturbed in the animal facility during stress tests, but were tested 
for hypersensitivity similarly to stressed animals.  
 
 
Single Prolonged Stress: The details of the single prolonged stress (SPS) protocol have been reported 
previously.70 Rats were exposed to serial stressors on one day as follows: restraint for 2 h, forced swim for 20 
min, and exposure to ether until general anesthesia was induced (generally under 5 minutes). Rats were single 
housed and left undisturbed in the animal facility for 7 days, a period crucial for the development of PTSS 
symptomatology.70 Following this period, fear conditioning, fear extinction, and extinction retention testing was 
conducted, as described previously.71 Control animals were also single housed and left undisturbed in the animal 
facility during the SPS procedure but experienced fear conditioning, fear extinction, and extinction retention 
testing similarly to stressed animals. 
 
DRG isolation and stimulation with 17β-estradiol 
Lumbar dorsal root ganglia (DRG) (L4-L6) were dissected from naïve, female Sprague Dawley rats (4-5 
weeks old) and digested with 2 mg/ml collagenase (Sigma, St. Louis, MO) and 5 mg/ml dispase II (Sigma, St. 
Louis, MO) in 1x HBSS at 37°C for 30 min. Cells were triturated with flame-polished Pasteur pipets, and plated 
at 2x105 cells/ml onto 96-well plates pre-coated with poly-D-lysine (Sigma, P7886) and Laminin (Sigma, St. 
Louis, MO). Twenty-four hours after plating, 1 µM cytosine β-D-arabinofuranoside was added.  DRG neurons 
were deprived of hormones by growing them in neurobasal A (Gibco, Waltham, MA) lacking phenol red, 
supplemented with 10% dextran-coated charcoal treated FCS, 50 µg/mL gentamicin, and murine nerve growth 
factor 2.5S (Gibco, Waltham, MA) for 72 hours. Stimulation with 100 nM 17β-estradiol (Sigma, St. Louis, MO) 
lasted for 3 or 6 hours. RNA was isolated after each time point using TRIzol (Invitrogen, Carlsbad, CA).  
RNA collection and isolation 
MVC cohort blood samples were collected in the ED at the time of enrollment using PAXgene RNA tubes. 
Total RNA (including miRNA) was isolated using the PAXgene blood miRNA kit (QIAGEN) and RNA was stored 
at -80 ˚C until use.  
For both stressed and non-stressed rats, blood and tissue RNA were collected immediately following pain or 
fear learning protocols. RNA was collected from animals in the single prolonged stress protocol via tail bleed 
immediately following CO2 euthanasia into RNAprotect Animal Blood Tubes (Qiagen, Germantown, MD). Total 
RNA was isolated using RNeasy Protect Animal Blood Kits (Qiagen) and stored at -80 ˚C until use. Plasma was 
 
 
collected from animals in the sound stress protocol by collecting trunk blood immediately following live 
decapitation. RNA was isolated from plasma using miRNeasy Serum/Plasma kits (Qiagen). Tissue RNA (aside 
from DRG for 17β-estradiol study, above) was collected by isolating the specific tissue and immediately storing 
in RNA later (ThermoFisher) according to manufacturer’s instructions. Animals used for tissue isolation were 
sacrificed via live decapitation without anesthesia, after which tissue samples (amygdala, hippocampus, 
hypothalamus, adrenal glands, DRG and peripheral nerve) were isolated within 30 min. Tissue was homogenized 
using Bashing Beads (Zymo Research, Irvine, CA) or a motorized homogenizer, RNA isolated using DirectZol 
(Zymo Research), and total RNA stored at -80˚C until use. 
For all RNA samples, RNA concentration and purity were measured using a NanoDrop One (Nanodrop 
Technologies, Wilmington, DE), and RNA integrity was measured using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). Only RNA meeting an RNA integrity score of 7 or greater were used in this 
study. 
 
Next Generation Sequencing  
Small RNAs: Template libraries for miRNA Next Generation Sequencing were produced from 1.0 µg total 
RNA using two similar protocols. An initial set of 69 samples (randomly selected from the full MVC cohort) were 
prepped using an adaptation of published protocols as described previously.21,72 A second set of 89 samples 
(also randomly selected) were prepped using TruSeq Small RNA library prep kits according to manufacturer’s 
specifications (Illumina, San Diego, CA). Six samples were library prepped using both methods. Twelve barcoded 
libraries were combined per lane and sequenced on a HiSeq 2000 (Illumina). Raw sequence reads were 
processed using a custom bioinformatics pipeline as described previously21, and were normalized using upper 
quartile normalization. In order to normalize potential technical biases between the two methods of library 
preparation, sequencing reads were adjusted for batch effects using the ComBat package in R.73 
Total RNA (excluding miRNA): Template libraries for total RNA sequencing were produced from 600ng total 
RNA using Ovation Human Blood RNA-Seq Library Systems kit (NuGen, San Carlos, CA) according to 
manufacturer’s specifications. Libraries were multiplexed in groups of six and sequenced on a HiSeq 2000 at 
the University of North Carolina at Chapel Hill High Throughput Sequencing Facility. Raw sequencing reads were 
 
 
aligned to the human hg19 genome assembly using STAR (version 2.4.2a).74 Expression level of each transcript 
were estimated via RSEM75 using University of California Santa Cruz (UCSC) known gene transcript and gene 
definitions. Raw RSEM read counts for all samples were normalized to the overall upper quartile76 before 
comparison and visualization. 
 
Reverse transcription-quantitative PCR  
miR-19b expression levels were measured in 26 samples from the MVC cohort using reverse transcription – 
quantitative PCR (RT-qPCR) according to the methods of Chen et al77. These samples were not part of the 
cohort that was used for RNA sequencing, thus they expanded the final cohort size to 178 participants. The 
samples were chosen based on case (PTSS and PTWP) control status at 6 months and were matched on age 
(within 5 years) and sex. Stem-loop RT primers and TaqMan probes for miR-19b and RNU48 detection were 
obtained from Life Technologies (Carlsbad, CA). 
miR-19b expression levels from animal model samples were measured via RT-qPCR using the same 
miR-19b RT primers and TaqMan probes as from human studies but used U87 as the control RNA. 
 
microRNA microarray 
Total RNA isolated from rat DRG was end-labeled with biotin and hybridized onto Affymetrx miRNA 4.0 
cartridge arrays. Total RNA was prepared using the Affymetrix FlashTag™ Biotin HSR RNA Labeling Kit and 
manual. Biotin-labeled RNA was then added to a hybridization cocktail (biotin-labeled total RNA, 50 pM control 
oligonucleotide B2, BioB, BioC, BioD and cre hybridization controls, 9.7 % DMSO, 4% formamide, 1x 
hybridization mix). Affymetrix miRNA 4.0 arrays (Affymetrix, Santa Clara, CA) were hybridized for 16 h at 48 °C 
in the GeneChip Hybridization Oven 645 (Affymetrix). The arrays were washed and stained with R-phycoerythrin 
streptavidin in the GeneChip Fluidics Station 450 (Affymetrix). The arrays were scanned with the GeneChip 
Scanner 3000 7G Plus with autoloader. GeneChip Command Console Software (AGCC) was used for washing, 
staining and scanning control of the instrumentation.  Affymetrix Expression Console Software was used for 
basic data analysis and quality control. 
 
 
 
 
Luciferase assays 
Cloning. The 3’UTRs of human genes RORA, NPAS2, and CLOCK were amplified from human 293T cell 
line genomic DNA using primers as indicated in Supplementary Table 3. The amplified 3’UTRs consisted of 
either the entire 3’UTR or a portion thereof, which preserved the relative location of the miR-19b binding site in 
the context of the full length 3’UTR. The resulting PCR products were cloned downstream of the firefly luciferase 
gene in pL-SV40-GL3 using XhoI and NotI or EcoR1 restriction enzyme sites. These newly created constructs 
were then mutated at the predicted miR-19b binding sites such that 2-3 mismatches were incorporated into the 
seed binding region (primers in Supplementary Table 3). 
Transfections/luciferase assays. Nine fmol pL-SV40-GL3 + 3’UTR and 36 fmol pL-SV40-Rluc were 
transfected into 293T cells using Lipofectamine 3000 (Invitrogen, Carlsbad, CA). Additionally, 136 fmol of an 
empty plasmid containing GFP was transfected into cells to monitor transfection efficiency. Six hours later, the 
media was replaced and the cells were transfected a second time with either 10 µM miR-19b mimic (Ambion, 
MC10629, Waltham, MA) or 10 µM negative control (Ambion, 4464058) using Lipofectamine RNAiMAX 
(Invitrogen). Seventy-two h later, cells were lysed and assayed for Luciferin protein levels using the Dual 
Luciferase Reporter Assay System (Promega, Madison, WI). Firefly and Renilla luciferase levels were quantified 
using a Synergy HTX multi-mode Reader (BioTek, Winooski, VT). The measured firefly luciferase luminescence 
was normalized by dividing by the corresponding sample’s Renilla luciferase luminescence. The normalized 
luminescence values from each triplicate were averaged. Change was measured by dividing the average 
luminescence of samples containing miR-19b mimic by the level form the negative control.  
  
 
 
Results 
 
In silico analyses identify miR-19 as a regulatory hub for the expression of genes involved in the pathogenesis 
of PTSS and PTWP 
Among all known human mature miRNAs (n=2,588, miRBase v21.0), 244 (9.4%) were predicted to target 
one or more gene transcripts previously associated with PTSS and pain outcomes (Figure 1a, range 1- 198). 
Monte Carlo simulations (x10,000) were used to determine the degree of preferentially predicted binding of each 
miRNA to transcripts associated with PTSS, pain, and PTSS and pain, while accounting for targeting distribution 
(Figure 1b). Based on these in silico analyses, the miR-19 family of transcripts was identified as most 
preferentially targeting PTSS and pain transcripts (p < 0.05, Figure 1b). The miR-19 family includes miR-19a 
and miR-19b (Supplementary Figure 1); these two miRNA have identical seed sequences, and thus similar 
predicted targeting, but originate from different genomic loci (miR-19a: 13q31.3, miR-19b: 13q31.3 and Xq26.2). 
Subsequent analyses focused on miR-19b as a potential pain and PTSS-regulatory hub, because it has been 
shown to be associated with PTSS, pain, and stress previously.21,23,24,35,78,79  
 
miR-19b predicts the development of PTSS and PTWP in humans following MVC 
To assess for evidence that miRNA-19b regulates the expression of genes involved in the pathogenesis of 
PTSS and PTWP, we evaluated whether miRNA-19b blood levels in the immediate aftermath of motor vehicle 
collision (MVC) predict PTSS and PTWP outcomes. Participants (n = 178) were drawn from a prospective cohort 
study of individuals presenting to the ED after MVC. Blood samples were obtained in the ED, and PTSS and 
PTWP outcomes were assessed at six months (Figure 2a). Most study participants were women less than 40 
years of age who presented to the ED within an hour of MVC (Table 1). miRNA blood levels were assayed using 
either RNAseq (n = 152) or RT-qPCR (n = 26). 
In initial general linear modeling (n = 152), a sex*miR-19b interaction was observed for both PTSS (OR = 
1.41, p = 0.039, Table 2) and PTWP outcomes (OR = 1.46, p = 0.031, Table 2). (These associations persisted 
after adjusting for prior trauma exposure.) Subsequent analyses were therefore stratified by sex. In such stratified 
analyses, miR-19b expression levels were lower in women who developed PTWP and substantial PTSS than in 
 
 
those who recovered (1.40-1.45 fold lower, p = 0.044 for PTSS, p = 0.026 for PTWP, Supplementary Table 4, 
Figure 2b, c). In contrast, miR-19b expression levels were higher in men who developed PTWP and substantial 
PTSS than in those who recovered (1.42-1.45 fold higher, p = 0.039 for PTSS, p = 0.113 for PTWP, 
Supplementary Table 4, Figure 2b, c). These observations were replicated in the 26 individuals from the MVC 
study in whom miRNA blood levels were assayed using RT-qPCR (Figure 2d). In secondary analyses using 
small RNAseq data, we also found that circulating blood miR-19a levels predicted PTWP and substantial PTSS 
in a sex-dependent manner (Supplementary Table 5). 
 
miR-19b is expressed in a sex-dependent manner in animal models of pain and PTSS 
We next evaluated whether this sex-dependent expression of miR-19b observed in our human MVC cohort 
was also present in animals exposed to paradigms known to produce stress-induced hyperalgesia (unpredictable 
sound stress model (USS)67,68) and altered fear learning (single prolonged stress (SPS) model,70,80 a model of 
PTSS) (Figure 3a). Because our human studies focused on blood expression levels of miR-19b, we first 
examined circulating levels of miR-19b in animals. In these samples, we found results paralleling our human 
data: male animals exposed to these paradigms demonstrated higher levels of circulating miR-19b as compared 
to unstressed control animals, whereas females demonstrated lower levels of miR-19b (Figure 3b, 3c).  
We next evaluated for sex differences in miR-19b levels in animal tissue known to be relevant to PTSS and 
PTWP pathogenesis. miR-19b was moderate-to-highly expressed in all tissues examined (Supplementary 
Figure 2a). When comparing expression levels between males and females, females expressed lower levels of 
miR-19b in all peripheral tissues (blood, DRG, peripheral nerve, and adrenal gland) but was expressed at equal 
levels in both sexes in all brain regions examined (amygdala, hippocampus, hypothalamus) (Supplementary 
Figure 2b). In male animals exposed to USS, miR-19b expression levels were increased in the amygdala and 
hypothalamus relative to male animals not exposed to USS (Figure 3d, 3e). This result was consistent with 
previous reports demonstrating increased miR-19b expression levels in the amygdala of male animals following 
stress exposure.23,35 However, in female animals exposed to USS, miR-19b expression levels in the amygdala 
and hypothalamus were similar to miR-19b expression in female animals not exposed to USS (Figure 3d, 3e).  
 
 
 
Estrogen stimulation of DRG neurons results in a decrease in miR-19b expression  
The above data demonstrate that miR-19b predicts PTSS and PTWP in a sex-dependent manner in humans, 
and is expressed at lower levels in females than males in human blood and animal tissue (see also 
Supplementary Figure 2b). These data, together with previous data showing that miR-19b is under the 
transcriptional control of the main female sex hormone 17β- estradiol,40 led us to hypothesize that 17β-estradiol 
regulates miR-19b expression in the peripheral tissues examined in this study. We therefore tested whether 17β-
estradiol stimulation alters miR-19b expression in female primary cultures of dorsal root ganglion (DRG) neurons. 
miR-19b expression decreased 3 hours following stimulation with 100 mM 17β-estradiol (1.23 fold lower, p < 
0.05, Supplementary Figure 3) but returned to baseline expression levels 6 hours following stimulation. As a 
positive control, we also assessed expression of CGRP mRNA expression following stimulation with 17β-
estradiol. Consistent with previous reports which show that CGRP is upregulated in response to estrogen (e.g.81), 
CGRP expression increased 3 and 6 hours after stimulation with 100 mM 17β-estradiol (1.90 fold higher, p < 
0.05, Supplementary Figure 3).  
 
Rhythmic processes are predicted to be over-represented in targeting by miR-19b 
The primary mechanism through which miRNA influence disease onset/outcomes is by regulating the 
expression of transcripts in biological pathways influencing pathogenic processes. A single miRNA can act as a 
gene regulatory hub by regulating many such transcripts. To identify potential biologic pathways regulated by 
miR-19b, we evaluated gene ontology (GO) relationships within miR-19b predicted targets using the DAVID 
online algorithm. The GO group with the highest fold enrichment was “rhythmic processes” (GO:0048511) (9.867 
fold enrichment, p = 1.5x10-5, Supplementary Table 6); this group included well-known circadian rhythm 
pathway genes such as CLOCK, NPAS, and PER1. Interestingly, this algorithm did not categorize the miR-19b 
predicted target, RORA, as a gene involved in rhythmic processes even though it is known to play a central role 
in the circadian rhythm.82 RORA is of interest because it has previously been associated with PTSS 
vulnerability.83,84 Additionally, evidence also implicates circadian and sleep dependent processes in pain, PTSS, 
and related neuropsychiatric disease pathogenesis.85-90 Overall, the results of GO bioinformatics predictions 
suggest that miR-19b may influence PTSS and PTWP outcomes by regulating circadian rhythm pathway genes. 
 
 
 
Circadian rhythm gene transcripts are negatively correlated with miR-19b expression levels in individuals who 
develop PTSS and/or PTWP following MVC and are directly regulated by miR-19b in vitro 
If miR-19b regulates circadian rhythm pathway genes in vivo, then individuals with high levels of miR-19b 
would be expected to have low levels of miR-19b targets (due to repression of the transcript by the miRNA). 
Consistent with this hypothesis, among individuals experiencing MVC a negative correlation was observed 
between miR-19b and key circadian rhythm transcripts RORA, CLOCK, and NPAS2 (except for men with 
NPAS2), and this relationship was stronger in individuals who developed PTSS/PTWP following MVC vs those 
who recovered (Figure 4a, 4b, 4c). The inverse relationship between miR-19b and CLOCK and RORA 
transcripts was also stronger in males than females, which is consistent with higher expression of miR-19b in 
male participants who develop PTSS/PTWP than female participants who developed PTSS/PTWP (see Figure 
2b, 2c). Using in vitro dual luciferase reporter assays, we also found that, consistent with bioinformatics 
predictions, miR-19b could directly bind and repress each of the 3’UTRs of these genes (Figure 4d, 4e, 4f). 
Together these data suggest that the influence of miR-19b on PTSS/PTWP development is due, at least in part, 
to miR-19b’s regulation of key circadian rhythm pathway transcripts. 
 
 
Discussion 
 
We evaluated the potential role of miRNA in the development of PTSS and PTWP using in silicio, in vitro, 
animal, and human data. Unbiased in silicio analyses implicated members of the miR-19 family in PTSS and 
PTWP pathogenesis, by having the highest degree of preferential predicted binding to PTSS and PTWP-
associated transcripts. Circulating miR-19b levels in the immediate aftermath of MVC were found to predict both 
substantial PTSS and PTWP six months after trauma exposure. Interestingly, associations between miR-19b 
levels and PTSS and PTWP outcomes were sex-dependent, with lower levels of miR-19b predicting PTSS and 
PTWP in women and higher levels predicting PTSS and PTWP in men. These associations and sex differences 
in associations were found in animal models of PTSS and PTWP, both in blood and in tissues relevant to PTSS 
and PTWP pathogenesis, and may be mediated in part by 17β-estradiol. Bioinformatics analyses indicated that 
gene pathways associated with circadian processes implicated in the development of adverse posttraumatic 
neuropsychiatric sequelae such as PTSS and PTWP were most likely to be targeted by miR-19b. Consistent 
with these data, in in vitro analyses miR-19b was found to directly bind and repress the 3’UTRs of key circadian 
rhythm transcripts, and a negative correlation was observed between miR-19b and these transcripts in humans 
experiencing MVC trauma, particularly those developing PTSS or PTWP.  
The molecular mechanisms accounting for the above associations between miR-19b and the development 
of substantial PTSS and PTWP, and sex differences in the direction of these associations, remain unknown. If 
miR-19b not only marks vulnerability to these outcomes, but also influences their development, then it is likely 
that miR-19b does so by altering the levels of key gene transcripts, such as those involved in circadian rhythm 
homeostasis. For example, in males, the higher levels of miR-19b expression associated with vulnerability to 
PTSS/PTWP would be expected to result in increased repression of key circadian rhythm regulators such as 
CLOCK, RORA, and NPAS2, and less robust activation of the circadian rhythm pathway. In women, the lower 
levels of miR-19b associated with vulnerability would be expected to have the opposite effect, resulting in more 
robust activation of the circadian rhythm pathway. Evidence suggests that disruption in circadian rhythm 
processing in either direction can have large downstream effects on rhythmic gene expression across multiple 
tissues and bodily systems.91-93 Thus from a global perspective it is possible that in both males and females miR-
 
 
19b expression levels that push biological systems too far from the mean in either direction are pathogenic. 
Further studies are needed to understand the mechanisms accounting for the association between miR-19b and 
PTSS and PTWP, and sex differences in the direction of these associations. 
Volk et al. and Balakathiresan et al. previously identified higher levels of miR-19b expression (in the 
amygdala and serum, respectively) in male animals exposed to chronic stress,23,35 and Wang et al. and Sakai et 
al. found that miR-19a was associated with chronic neuropathic pain in male rats.36,94 In humans, Martin et al. 
identified miR-19a as the most differentially up-regulated miRNA in male combat veterans who developed 
PTSD.25 Our findings in male animals and humans are consistent with these data, but extend them and place 
them in sex-specific context, as miR-19a consistently predicts substantial PTSS and PTWP in females, but in a 
direction opposite to males. These data highlight the importance of evaluating potential sex-specific effects on 
stress-related disorder pathogenesis, as studies examining both sexes would likely not identify an association 
between miR-19a/b and these outcomes unless specifically stratifying for sex. Our results indicate that 17-β-
estradiol may contribute to the lower levels of miR-19b observed in females. Although not experimentally tested 
in the current study, it is likely that 17-β-estradiol regulation of miR-19b is indirect, based on the fact that we did 
not bioinformatically identify an estrogen response element in the promoter region of miR-19b. In addition to 
regulation by 17-β-estradiol, it is also possible that miR-19b is regulated in a sex-dependent manner via other 
sex hormones or via non-hormonal mechanisms. For instance, X chromosome-specific regulatory events, such 
as X chromosome inactivation, might also influence miR-19b levels, as this miRNA originates from two 
evolutionary paralogous genomic regions, one on chromosome 13 and the other on the X chromosome. 
Of note, while our analyses focused on miR-19b, our in silico analyses identified a number of other miRNA 
that may also influence posttraumatic pain and PTSS pathogenesis and/or maintenance. Many of these miRNA, 
including miR-30, miR-181, miR-15, and miR-124, have already been shown to be associated with stress-related 
disorders.33,95-98 It should be noted, however, that while our in silico selection criteria prioritized miRNA that bind 
many gene targets, other miRNA not selected as top candidates using this method may also have an important 
influence on PTSS or posttraumatic pain if they affect the expression of one or only a few genes, but these genes 
are highly influential. Examples of such miRNA include miR-13521,34,99,100, miR-103101,102, and miR-32022,65,103-106.  
 
 
miR-19b originates from both the miR-17-92 cluster (chromosome 13) and the miR-106a-363 cluster (X 
chromosome). In this study, we did not examine the role of other members of these two clusters on PTSS and 
PTWP outcomes following MVC. However, it is interesting to note that the miR-17/20/106 family of miRNA, that 
originates from the same genomic regions (and is regulated by the same promoter region), was identified as a 
candidate regulatory hub in in silico analyses. Therefore, these miRNAs might also predict PTSS/PTWP 
development following trauma exposure in a sex-dependent manner. As additional evidence suggests that this 
might be the case, using the online bioinformatics algorithm DIANA miRPath107, these three miRNA are also 
predicted to preferentially target the circadian rhythm pathway. 
The fact that miR-19b regulates multiple key transcripts involved in the circadian rhythm pathway is 
interesting given the wealth of (albeit conflicting) literature linking this pathway to PTSS vulnerability. For 
instance, RAR-related orphan receptor alpha (RORA), which we showed to be strongly regulated by miR-19b in 
this study, has been shown to be both genetically associated83,84,108 and not associated109 with PTSD. Additional 
studies have also shown physiological relationships between the circadian rhythm and PTSD pathogenesis,110 
and literature from the pain field also implicates sleep and circadian abnormalities to pain vulnerability86,87,111-114. 
However, very few studies have examined whether there are sex-dependent differences in the contribution of 
the circadian rhythm pathway to PTSS/PTWP pathogenesis. This study adds evidence to this growing body of 
literature implicating the circadian rhythm pathway and core circadian rhythm genes in the pathogenesis of pain 
and PTSS development. Future studies examining the influence of sleep and the circadian rhythm pathway on 
pain and PTSS outcomes should include sex as a variable.  
The many strengths of this study include being one of the largest human studies of miRNA predictors of 
PTSS and PTWP development in male and female trauma survivors to date, and that it used coordinated 
translational studies (in silico, human cohort, animal, and molecular/cell culture experiments) to guide and 
strengthen the validity of the findings. However, several limitations should be considered when interpreting this 
work. First, the main findings of the study have not been replicated in a second cohort of post-trauma survivors. 
This is an essential next step for future studies. However, this study did internally replicate the RNA sequencing 
findings (both technically and biologically) by examining miR-19b expression in an expanded cohort of 26 age-
matched cases and controls using RT-qPCR. Second, this study did not assess the influence of 17-β-estradiol 
 
 
levels on miR-19b association with PTSS/PTWP in female participants following MVC. This would have been an 
interesting experiment given the cell culture results demonstrating that 17-β-estradiol can negatively regulate 
miR-19b in neuronal tissue. Third, this study focused on the experimental validation of only a subset of the many 
predicted targets of miR-19b, those of the circadian rhythm pathway. This decision is supported by strong 
bioinformatics pathway analyses, however, it is possible that other transcripts predicted to be regulated by miR-
19b are also important to the pathogenesis of PTSS/PTWP. Finally, this work was performed in only African 
American individuals and in one strain of rats. Therefore, whether there are also ethnic/strain differences in the 
association between miR-19b and PTSS/PTWP is not known.  
In summary, we report the first set of evidence indicating that miR-19b is differentially regulated in males and 
females following trauma and that expression levels of miR-19b in the early aftermath of MVC predict PTSS and 
PTWP outcomes in men and women. Further, this data suggests that miR-19b may affect the development of 
these stress-related disorders by altering the levels of key circadian rhythm gene transcripts. Future studies are 
needed to delineate the sex-dependent effects of miR-19b on circadian rhythm signaling and on adverse 
posttraumatic outcomes.  
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Figure 1. In silico analyses indicate that miR-19 is a strong candidate regulatory hub for both 
pain and PTSS. (a) 244 miRNA (indicated by each blue dot) target at least one pain/PTSS 
gene.  miR-19 is predicted to target 112 of 629 pain/PTS genes. (b) Of the miRNA targeting the 
most pain/PTS genes, miR-19 is the strongest predicted regulatory hub for pain and PTSS, 
indicated by high combined values of the negative logarithm of the empirical p-value (p <0.002, 
green dotted line) for pain (gray circles) and PTSS (gray squares).  
b 
P = 0.002 
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Table 1. Baseline characteristics of study participants  (n = 178) 
Characteristic  
Enrolled, n 178 
Age, years, mean (SD) 34 (12) 
Females, n (%) 112 (63) 
Education, n (%)  
HS or less 68 (39) 
Some college 77 (43) 
College 25 (14) 
Post-college 7 (4) 
Collision characteristics  
     Driver, n (%) 121 (68) 
     Severe vehicle damage, n (%) 106 (60) 
     Seatbelt worn, n (%) 143 (80) 
     Airbag deployed, n (%) 63 (35) 
Location of vehicle damage  
     Front, n (%) 81 (46) 
     Rear, n (%) 54 (30) 
     Right side, n (%) 38 (21) 
     Left side, n (%) 29 (16) 
Distress* in the early aftermath of trauma, mean (SD)  23 (11) 
Overall pain in the ED (0-10 NRS), mean (SD) 7.3 (2.2) 
Median time to ED, minutes 60 
Number of previous life events**, mean (SD) 3.5 (2.7) 
IESR score at 6 months, mean (SD) 31 (26) 
Overall pain at 6 months, mean (SD) 5.2 (3.3) 
*Distress measured with the peritraumatic distress inventory (scale of 0-52) 
**Life events checklist (assess 16 different types of trauma plus a question about 
‘other trauma’) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Logistic regression models examining the relationship between 
Emergency Department levels of miR-19b expression and Posttraumatic 
Stress (PTSS) or Posttraumatic Widespread Pain (PTWP) six months after 
Motor Vehicle Collision (n = 152).   
 PTSS PTWP 
Variablea OR (95% CI)b p value OR (95% CI)b p value 
miR-19b 0.86 (0.59, 1.27) 0.462 0.74 (0.47, 1.12) 0.190 
     x stress 0.99 (0.98, 1.01) 0.735 1.00 (0.99, 1.02) 0.693 
     x sex 1.41 (1.02, 1.95) 0.039 1.46 (1.04, 2.06) 0.031 
Stress 1.06 (1.00, 1.13) 0.051 1.05 (0.99, 1.12) 0.131 
Sex 0.78 (0.19, 3.10) 0.726 0.33 (0.08, 1.39) 0.131 
Age 1.00 (0.97, 1.05) 0.660 1.03 (0.99, 1.07) 0.088 
aSite was also included in the model as a categorical variable. bOR = odds ratio, CI = 
confidence interval.  
 
 
a 
b 
 
c 
d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. miR-19b is differentially expressed in male and female individuals who develop posttraumatic 
stress symptoms (PTSS) and/or posttraumatic widespread pain (PTWP) following motor vehicle collision 
(MVC). (a) Simplified study design schematic showing that women and men were enrolled in the ED 
following MVC, blood samples were obtained in the ED, and PTSS and PTWP outcomes were assessed 
at six months. (b) miR-19b expression levels (n=152) in male (blue) and female (red) participants who 
developed low versus high levels of PTSS following MVC as measured by miRNA sequencing. (c) miR-
19b expression levels (n=152) in male (blue) and female (red) participants who develop low versus high 
levels of PTWP following MVC as measured by miRNA sequencing. (d) RT-qPCR data showing relative 
miR-19b expression levels in individuals who recover following MVC versus those who develop both 
PTSS and PTWP six months following MVC. Data are represented as mean + SEM. *p < 0.05.  
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Figure 3. miR-19b is expressed differently in male and female rats following stress exposure. Sex-
dependent association of miR-19b with pain and PTS symptoms in humans and animals. (a) Schematic 
diagram of the animal protocol used to assess sex-dependent differences in miR-19b expression. Male 
and female Sprague Dawley rats were either unstressed or exposed to unpredictable sound stress (USS) 
or single prolonged stress (SPS). All animals were assessed for hyperalgesia or fear conditioning 14 or 
7 days following stress exposure, and blood and brain were isolated immediately following. (b) 
Circulating miR-19b expression levels in male (blue, n=12) and female (red, n=12) rats unstressed or 
exposed to USS. (c) Circulating miR-19b expression levels in male (blue, n=28) and female rats (red, 
n=19) unstressed or exposed to SPS. (d) miR-19b expression levels in the amygdala of male (blue, 
n=12) and female rats (red, n=12) unstressed or exposed to USS. (e) miR-19b expression levels in the 
hippocampus of male (blue, n=12) and female rats (red, n=12) unstressed or exposed to USS. Data are 
represented as mean + SEM. *p < 0.05 
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Figure 4. Evidence for miR-19b regulation of circadian rhythm genes in human cohort samples and 
in cell culture studies. (a and b) Correlation between circulating miR-19b expression levels and 
circulating mRNA expression levels in male (blue) and female (red) participants in the early aftermath 
of MVC (n=90) (a) miR-19b correlation with RORA mRNA in individuals who developed PTWP 6 
months following trauma exposure (colored) versus those who recovered (gray), (b) miR-19b 
correlation with CLOCK mRNA, and (c) miR-19b correlation with NPAS2 mRNA. Expression levels 
represented on the y-axis represents RNA seq reads (x1000). Pearson correlation coefficients (r) and 
p values were calculated using bivariate analyses for male and female participants together (except 
for NPAS2, which is for female only), but regression lines are representative of males and females 
separately. (d-f) Dual luciferase reporter assays examining direct binding of miR-19b to (d) RORA, (e) 
CLOCK, and (f) NPAS2. Black bars indicate binding of miR-19b mimic or control mimic to wild type 
3’UTRs while gray bars represent binding of miR-19b or control mimic to 3’UTRs with miR-19b seed 
sites mutated as indicated. Predicted miR-19b – target hybrids are shown below each graph; RORA 
and CLOCK are predicted to have two miR-19b binding sites each.  
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  Supplementary Table 1.  Pain-associated genes (n = 560) compiled from three established 
databases (PainNetworks,42 Algynomics,43 and PainGenes44).  These genes were used in 
bioinformatics analyses to determine which miRNA are predicted to target the genes vs. random sets 
of genes. 
ABCC4 ACE2 ACHE ACPP ACSL1 ADAM11 ADAMTS5 ADCY5 ADCYAP1 ADCYAP1R1 ADM 
ADORA2A ADORA2B ADRA1A ADRA1B ADRA1D ADRA2A ADRA2C ADRB1 ADRB2 ADRB3 
ADRBK1 ADRBK2 AGTR2 ALOX12 ANO1 ANO3 APP AQP1 AQP4 ARL5B ARRB1 ARRB2 ASIC1 
ASIC2 ATF1 ATF3 ATF6B ATP1A1 ATP1B3 ATP2B1 ATP6V1A ATP6V1B2 ATP6V1G2 AVPR1A 
AVPR2 BACE1 BAMBI BDKRB2 BDNF BHLHE22 BTG2 CA8 CACNA1A CACNA1B CACNA1E 
CACNA1G CACNA1H CACNA2D1 CACNA2D2 CACNA2D3 CACNB3 CACNG2 CALB1 CALCRL 
CALM2 CAMK2A CAMK2B CAMK4 CAT CCL2 CCL3 CCL4 CCR1 CCR7 CD274 CD38 CD4 CD40 
CDH11 CDK5 CDK5R1 CDKN1A CHRM1 CHRM2 CHRM3 CHRM5 CHRNA5 CHRNA7 CHRNB2 
CHRNB4 CHUK CLCN6 CLOCK CNGA3 CNR1 COL11A2 COL9A1 COMT COQ10A CPN1 CREB1 
CRHR1 CRHR2 CRIP2 CRYAA CSF2 CSF2RB CSK CSNK1A1 CSNK1E CTSB CTSS CX3CL1 
CXCL5 CXCR3 CXCR4 CYBB CYP19A1 CYP2D6 CYP3A4 DAB1 DBH DBI DICER1 DISC1 DLG2 
DLG4 DPCR1 DPP4 DRD1 DRD2 DRGX DTNBP1 DUSP6 ECE2 EDN1 EDNRA EDNRB EFNB1 
EFNB2 EGF EGFR EGR1 EGR3 ENPP2 EPB41L2 EPHB1 EPHB2 EPHB3 EPHB4 EPHB6 EPHX2 
ERBB2 ERBB4 EREG ESR1 ESR2 ETV1 EZR F2R F2RL1 F2RL2 FAM19A4 FGF2 FKBP5 FLOT1 
FMR1 FOS FOSB FOSL2 FOXN1 FRMPD4 FSTL1 FYN GABARAPL1 GABBR1 GABBR2 GABRA4 
GABRA6 GABRB1 GABRB2 GABRB3 GABRG2 GAD1 GALR1 GBP1 GBP2 GCH1 GDNF GFAP 
GFRA2 GHR GHRHR GJA1 GLRA1 GLRA2 GLRA3 GLRA4 GLRB GNAO1 GNAQ GNAZ GNB2L1 
GNG5 GPR3 GPR55 GPSM3 GRASP GRIA1 GRIA2 GRIA4 GRIN1 GRIN2A GRIN2B GRIN2D 
GRIN3A GRIN3B GRK5 GRK6 GRK7 GRM1 GRM2 GRM4 GRM5 GRN GRP GUCY1B3 HCN1 HCN2 
HCRT HDAC4 HDC HIF1A HINT1 HMGB1 HMOX2 HN1 HNRNPD HNRNPU HOXB8 HRH1 
HSD17B8 HSPA8 HSPA9 HTR2A HTR2C IAPP ICA1 IER3 IFNG IFRD1 IGF1 IKBKAP IKBKB IKBKE 
IL10 IL13 IL17A IL1A IL1R1 IL1RAP IL1RN IL2 IL21R IL22RA2 IL2RA IL2RB IL33 IL4 IL6 IL6ST IL7R 
INADL IRF8 ITPR1 JUN KCNA1 KCNA2 KCND2 KCNIP3 KCNJ11 KCNJ3 KCNJ5 KCNJ6 KCNJ8 
KCNJ9 KCNK10 KCNK2 KCNK3 KCNK9 KCNS1 KCNT1 KCTD17 KIF1A KIT KLF11 KLF7 KRAS 
L1CAM LAMA4 LEP LEPR LGALS1 LMX1B LPAR1 LPAR3 LPAR5 LRP1 LTA LTB LYN LYST MAOA 
MAOB MAP2K1 MAP2K3 MAP3K8 MAPK1 MAPK10 MAPK11 MAPK14 MAPK3 MAPK8 MAPK9 
MAPT MCCD1 MCF2L MDC1 MECP2 MGLL MIF MME MMP24 MPDZ MPZ MSNMTDH MTHFR 
MUC21 MYD88 NAV2 NBL1 NCAM1 NDN NEDD4L NF1 NFE2L2 NFKB1 NFKBIA NFKBIZ NGF 
NGFR NLGN2 NLRP3 NOS1 NOVA1 NOX1 NPEPPS NPPC NPTX1 NPY1R NPY2R NR2C2 NR2F6 
NR3C1 NR4A1 NRG1 NRM NT5E NTF3 NTRK2 NTRK3 NTSR1 NTSR2 OPRK1 OPRL1 OSM OXTR 
P2RX2 P2RX3 P2RX5 P2RX7 P2RY1 P2RY13 P2RY2 P2RY6 PACSIN1 PAK7 PAWR PBX2 PCSK2 
PCSK6 PDGFB PDYN PER1 PER2 PIK3CA PIK3CB PIK3CG PIP5K1A PIP5K1B PIP5K1C PIRT 
PLA2G4A PLCB1 PLCB3 PLCB4 PLCG1 PLCL1 PLP1 PMP22 PNOC POMC POU5F1 PPARA 
PPARG PPP1R1B PPP1R9B PPP3CA PPP3R1 PPP3R2 PPT2 PRKAA2 PRKACA PRKACB 
PRKAG2 PRKAR1B PRKCA PRKCB PRKCD PRKCE PRKD1 PRKD3 PRKG1 PRLR PRNP PROK2 
PRRT1 PRX PSMB8 PSMB9 PTAFR PTGDR PTGER2 PTGER3 PTGER4 PTGFR PTGIR PTGS1 
PTGS2 PTN PTPRZ1 RAB5A RABGGTA RAD52 RAF1 RAP1A RASD2 RELA RELN RET RGS2 
RGS4 RGS9 RNF5 RPS6KA3 RUNX1 RUNX2 RUNX3 RXRB S100A10 S100B S1PR3 SCD SCN10A 
SCN1A SCN2A SCN2B SCN3A SCN5A SCN8A SCN9A SESN2 SET SGK1 SHC1 SIGMAR1 
SLC12A2 SLC12A5 SLC12A6 SLC15A2 SLC17A6 SLC17A7 SLC17A8 SLC18A2 SLC1A3 SLC29A1 
SLC32A1 SLC39A7 SLC6A1 SLC6A11 SLC6A3 SLC6A4 SLC6A6 SOD2 SPARC SPP1 SPTLC1 
SRD5A1 SRR STARD13 STAU1 STAU2 STK39 STOML3 STX1A TAC1 TAC4 TACR1 TACR3 TAP1 
TAP2 TCF19 TCIRG1 TGFB1 TH THBS4 TLR3 TLR4 TLR5 TLR9 TMSB10 TMSB4X TNF TNFAIP3 
TNFRSF1A TNFRSF1B TNXB TRIM10 TRIM26 TRPA1 TRPM3 TRPV2 TRPV3 TRPV4 TUBB 
TYRP1 UCP2 VDR VEGFA VIP VPS4A VPS4B VPS52 WNK1 YWHAZ YY1 ZEB2 ZFAND5 ZFAND6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 2. PTS- (or related neuropsychiatric disorder) associated genesa (n = 154) 
identified using a systematic literature review as described in methods. These genes were used in 
bioinformatics analyses to determine which miRNA are predicted to target the genes vs. random sets 
of genes.  
ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRBK2, ARRB2, COMT, SLC6A2, TH 
CNR1, FAAH, ARNTL, BHLHB2, CCK, CCKAR, CLOCK, HCRTR1, NPAS2, OPN4, PER1, PER2, 
PER3, RORA, RORB, TIMELESS, TEF, DBH, DRD1, DRD2, DRD3, DRD4, DBI, GABBR1, GABRA1, 
GABRA2, GABRA3, GABRA6, GABRB1, GABRB2, GABRB3, GAD1, GAD2, SLC6A11, ANK3, 
CAMK2A, DAO, DAOA, GRIK1, GRIK4, GRIN1, GRIN2A, GRIN2B, GRM1, SLC1A1, ADCYAP1, 
ADCYAP1R1, CCKBR, CLPS, CPS1, CRH, CRHBP, CRHR1, CRHR2, FKBP5, GAL, NPY, NPY1R, 
NPY2R, NPY5R, NR3C1, NR3C2, SLC18A1, TULP1, ACE1, ACHE, F5, IL10, IL17, IL18, IL1A, IL1B, 
IL1R2, IL1RN, IL2, IL6, IL8, TNF, TNFRSF1A, OPRD1, OPRK1, OPRL1, OPRM1, PDYN, PENK, 
PNOC, POMC, BDNF, OXT, OXTR, PRL, TAC1, HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR3B, 
MAOA, MAOB, SLC6A3, SLC6A4, TPH1, TPH2, AMTN, ARAP3, CACNA1C, CSMD1, CTSF, 
DICER1, DGKH, EGFR, FGF1, FGF2, FGFR2, GDA, GFOD1, HYI, ITIH1, JAM3, KCNT2, KLHL13, 
KIT, MAMDC1, MCTP1, MYO5B, NFIA, PDE4D, PLSCR4, PTN, PTPRG, REG3A, RBMS3, SORCS2, 
STAB1, SYNE1, TCF4, TDRD9, TECTA, TMEM16C, TMEM16D, TRDN, TSPAN8, VGCNL1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 3. Primers used in the study 
Primer Sequence Construct 
F-CLOCK CATGACCTCGAGTTACAGGTGTGAGCACCTTTCC pL-SV40-GL3-CLOCK-3’UTR 
R-CLOCK CATGACGCGGCCGCACCTCCAGTCCAAGAGACTGAT pL-SV40-GL3-CLOCK-3’UTR 
F-NPAS2 CATGACCTCGAGAGTCGGGACACAATCAGCTT pL-SV40-GL3-NPAS2-3’UTR 
R-NPAS2 CATGACGCGGCCGCTGGAATGTTGGCTGGCATGA pL-SV40-GL3-NPAS2-3’UTR 
F-RORA ACTACTCTCGAGTCTTTTGGTGATCGGGGTCA pL-SV40-GL3-RORA-3’UTR 
R-RORA ACTACTGCGGCCGCTTCCCTCACCCTCCTATCCA pL-SV40-GL3-RORA-3’UTR 
F-CLOCK-mutA AGGATTGGTACCGCTTTATTTTAGGTGGCTG pL-SV40-GL3-CLOCKmutA-3’UTR 
R-CLOCK-mutA GCGGTACCAATCCTATTTTCAAACATAATTG pL-SV40-GL3-CLOCKmutA-3’UTR 
F-CLOCK-mutB AAATTGGTACCCAAAACATCTTAGGCACTTT pL-SV40-GL3-CLOCKmutB-3’UTR 
R-CLOCK-mutB TTTGGGTACCAATTTTACCTCTATAACTGAAAC pL-SV40-GL3-CLOCKmutB-3’UTR 
F-NPAS2-mut TAATTGGTACCGCTACACAGAGGAAATAACT pL-SV40-GL3-NPAS2mut-3’UTR 
R-NPAS2-mut GTAGCGGTACCAATTAAAACAAAAACAACCATT pL-SV40-GL3-NPAS2mut-3’UTR 
F-RORA-mutA TTACTTGGTACCACTAGCTCTTTGTTTCATGA pL-SV40-GL3-RORAmutA-3’UTR 
R-RORA-mutA TAGTGGTACCAAGTAATGCCGCAACCTCCGCT pL-SV40-GL3-RORAmutA-3’UTR 
F-RORA-mutB TCATTTGGTACCTTTTTCTTTAAATTAAATGC pL-SV40-GL3-RORAmutB-3’UTR 
R-RORA-mutB AAAAGGTACCAAATGAAAGTGCCTTATCAATT pL-SV40-GL3-RORAmutB-3’UTR 
 
 
 
 
 
miR-19a    -UGUGCAAAUCUAUGCAAAACUGA-- 13q.31.3 
miR-19b-1  -UGUGCAAAUCCAUGCAAAACUGA-- 13Q.31.3 
miR-19b-2  -UGUGCAAAUCCAUGCAAAACUGA-- Xq26.2 
  
Supplementary Figure 1. miR-19 genomic loci and sequences. a) miR-19a and miR-19b-1 are 
expressed as part of the miR-17-92 polycistronic miRNA cluster on chromosome 13. miR-19b-2 is 
expressed as part of the miR-106a-363 miRNA cluster on the X chromosome. b) the sequence of 
miR-19a and miR-19b miRNAs are identical except for one nucleotide that is shown in bold font. The 
miR-19 seed sequence is greyed.  
a 
b 
 
 
 
 
  
Supplementary Table 4. miR-19b expression levels in male and female individuals who develop  
Posttraumatic Stress symptoms (PTSS) or Posttraumatic Widespread Pain (PTWP) six months 
after Motor Vehicle Collision versus those who recover. 
 Male (n = 58) Female (n = 95) 
 miR-19b expression in 
individuals developing PTSS or 
PTWP/ recover (Fold Diff)a 
p valueb 
miR-19b expression in 
individuals developing PTSS or 
PTWP/ recover (Fold Diff)a 
p valueb 
PTSS 5099 / 3579 (1.42) 0.039 2787 / 3906 (-1.40) 0.044 
PTWP 4915 / 3396 (1.45) 0.113 2648 / 3832 (-1.45) 0.026 
aFold difference was determined by dividing the mean sequencing reads in individuals who developed PTSS or PTWP  
by the mean sequencing reads in individuals who recovered. bp values were determined using Student’s T-tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 5. Logistic regression models examining the relationship 
between Emergency Department levels of miR-19a expression and  
Posttraumatic Stress Symptoms (PTSS) or Posttraumatic Widespread Pain 
(PTWP) six months after Motor Vehicle Collision (n = 152).   
 PTSS PTWP 
Variablea OR (95% CI)b p value OR (95% CI)b p value 
miR-19a 0.84 (0.34, 2.09) 0.704 0.53 (0.19, 1.49) 0.228 
     x stress 0.99 (0.95, 1.02) 0.418 1.00 (0.97, 1.04) 0.831 
     x sex 2.65 (1.11, 6.32) 0.028 2.43 (1.05, 5.65) 0.039 
Stress 1.07 (1.01, 1.13) 0.016 1.05 (0.99, 1.11) 0.066 
Sex 0.82 (0.23, 2.95) 0.762 0.42 (0.12, 1.52) 0.187 
Age 1.01 (0.97, 1.05) 0.615 1.03 (0.99, 1.07) 0.094 
aSite was also included in the model as a categorical variable. bOR = odds ratio, CI = confidence 
interval.  
 
 
  
Supplementary Figure 2. Relative expression of miR-19b in blood and tissue samples relevant to 
pain/stress/PTS. a) Blood expression levels (“Circ”) were measured in male and female human (n = 
26) and animal (n ≥ 12) samples; tissue expression levels were measured in rats only. Expression 
levels of miR-19b were assayed using RT-qPCR and expressed as normalized average cycle 
threshold values subtracted from the total number of cycles. Therefore, the lowest levels of expression 
are in DRG and peripheral nerve tissues. b) Relative expression of miR-19b in male (blue bars) and 
female (red bars) human and animal tissues. Results are the average of technical duplicates and 
standard errors represent error across all humans and animals assayed. DRG = dorsal root ganglion. 
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Supplementary Figure 3. Effect of 17β-estradiol stimulation of primary dorsal root ganglia neurons 
on miR-19b expression levels. CGRP mRNA expression levels were measured as a positive control. 
miR-19b expression levels decreased 3 hours following stimulation with 17β-estradiol while CGRP 
mRNA expression levels increased. Expression levels of each RNA were measured using RT-qPCR; 
miR-19b expression changes were also validated using a microarray. Error bars represent the 
average of biological duplicates performed in technical duplicate. Statistical significance (* p < 0.05) 
represents significant difference in expression relative to baseline (“control”, no estradiol added). 
 
 
 
 
 
 
 
 
 
Supplementary Table 6.  Gene Ontology* relationships of miR-19b predicted targets (from pain and 
posttraumatic stress symptoms gene lists) 
Gene Ontology 
# 
Genes 
Fold 
Enrichment 
P value List of genes 
GO:0048511 
rhythmic process 
8 9.867 1.5x10-5 
NPAS2, EGR3, EREG, GRIN2A, PER1, CHRNB2, CLOCK, 
OPN4 
GO:0050896 
response to 
stimulus 
 
43 1.938 2.9x10-6 
PPARA, IL1R1, ERBB4, IL6ST, NPY2R, DICER1, GJA1, KIT, 
EDNRB, PLCL1, NPAS2, TNFRSF1B, KRAS, CNR1, IL1RAP, 
VPS4B, PER1, STK39, PRKACB, PRKAA2, PLCB1, GHR, SGK1, 
PIK3CB, MAP2K3, NF1, ESR1, GRIN2A, IGF1, CNGA3, HDAC4, 
MAPK1, GRM4, HIF1A, ADRB1, GNAQ, EREG, MAPK14, 
CHRNB2, MAPK8, CACNA1C, CLOCK, OPN4 
GO:0032502 
developmental 
process 
37 1.856 7.4x10-5 
ZFAND5, PPARA, GDA, ERBB4, DICER1, ANO1, GJA1, KIT, 
RORA, EPHB3, EDNRB, NPAS2, KRAS, EGF, RUNX3, GHR, 
KLF7, EGR3, PIK3CB, YY1, NF1, SCN2A, EFNB2, FMR1, 
GRIN2A, IGF1, HDAC4, MAPK1, HIF1A, ADRB1, EREG, GNAQ, 
MAPK14, CHRNB2, MAPK8, SCN8A, CDH11 
GO:0051179 
localization 
35 1.846 1.5x10-4 
ZFAND5, PPARA, SCN3A, GABRB2, GLRA3, ANO1, NR3C2, 
GJA1, ATP6V1B2, KIT, KCNK10, EDNRB, KRAS, ANO3, VPS4B, 
GHR, TRPM3, SGK1, SLC6A11, SCN2A, FMR1, WNK1, 
GRIN2A, CNGA3, KCNK2, MAPK1, GRM4, HIF1A, SLC17A6, 
KCNJ6, SLC6A6, CHRNB2, SCN8A, CLCN6, CACNA1C 
GO:0032501 
multicellular 
organismal 
process 
 
48 1.771 5.8x10-6 
ZFAND5, PPARA, GDA, ERBB4, GABRB2, GLRA3, DICER1, 
ANO1, NR3C2, GJA1, RORA, KIT, EPHB3, EDNRB, NPAS2, 
KRAS, CSF2RB, PLCB1, EGF, RUNX3, GHR, KLF7, EGR3, 
PIK3CB, YY1, MAP2K3, NF1, SCN2A, EFNB2, FMR1, GRIN2A, 
IGF1, CNGA3, HDAC4, MAPK1, GRM4, ADRB1, HIF1A, 
SLC17A6, GNAQ, EREG, MAPK14, CHRNB2, MAPK8, SCN8A, 
CACNA1C, CDH11, OPN4 
GO:0065007 
biological 
regulation 
67 1.413 2.1x10-5 
PPARA, FOSL2, IL6ST, DICER1, GJA1, RORA, KCNK10, 
EDNRB, IL1RAP, PIK3CA, CSF2RB, PRKACB, PLCB1, GHR, 
EGR3, PIK3CB, YY1, MECP2, ESR1, GRIN2A, WNK1, CNGA3, 
HNRNPU, MCTP1, MAPK1, GRM4, ADRB1, HIF1A, GNAQ, 
EREG, MAPK8, TNFAIP3, CLOCK, ZFAND6, IL1R1, ERBB4, 
NPY2R, NR3C2, KIT, EPHB3, PLCL1, NPAS2, TNFRSF1B, 
KRAS, CNR1, HNRNPD, PER1, ETV1, PRKAA2, EGF, RUNX3, 
KLF7, MAP2K3, NF1, RAF1, IGF1, HDAC4, SLC17A6, MAPK14, 
GRK6, RAP1A, CHRNB2, SCN8A, CACNA1C, CLCN6, NFIA, 
OPN4 
*determined using DAVID: https://david.ncifcrf.gov/home.jsp 
